Arcturus Therapeutics Holdings Inc. (ARCT)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore ≥ 3 before any bullish entry, and ARCT also fails the $5M 20-day average dollar-volume floor at $3.63M.
Company overview
Arcturus Therapeutics Holdings Inc. is a biotechnology company specializing in RNA-based medicines, focusing on vaccines for infectious diseases and treatments for rare liver and respiratory conditions. Key programs include LUNAR-OTC for ornithine transcarbamylase deficiency and LUNAR-CF for cystic fibrosis. The company has strategic partnerships with firms like Janssen Pharmaceuticals and Ultragenyx Pharmaceutical.
Fundamental
weakArcturus has a strong cash position but faces significant revenue and profitability challenges.
Arcturus has meaningful cash runway for a biotech (about $191.5M cash at 2026-06-30, minimal debt, and management guidance pointing to runway through year-end 2028). But revenue has fallen steeply and losses remain large (TTM net margin around -392% and negative free-cash-flow yield around -31%), so the story is still dominated by clinical/commercial execution risk rather than steady earnings power.
Sentiment
fairSentiment is mixed with no clear forward-dated catalysts to drive momentum.
Last ~2 weeks coverage is centered on the Aug 6 Q2 results/pipeline update (announced), which read mildly constructive on EPS but with revenue still light, while repeated bearish rating-change headlines kept sentiment two-sided. Baseline sentiment delta is indeterminate (no baseline articles passed the primary-tier filter), and a moderate red-flag cap applies due to conflicting actionable catalysts; no regulator-confirmed investigations surfaced.
Technical
goodThe stock shows strong short-term trend and momentum, but liquidity is insufficient for action.
Score 4: ARCT has a strong short-term trend/momentum profile with price above SMA20/50/200, EMA9/21 and daily VWAP, while MACD is positive and above signal and ADX 45.18 confirms trend strength. The main deductions are extension risk (RSI14 71.33, Williams %R -8.59) and insufficient 20-day liquidity for this strategy.
You’re looking at 2026-08-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.